103 related articles for article (PubMed ID: 33064325)
1. Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
Amelot A; Terrier LM; Le Nail LR; Cristini J; Cook AR; Buffenoir K; Pascal-Moussellard H; Carpentier A; Dubory A; Mathon B
Prostate; 2021 Feb; 81(2):91-101. PubMed ID: 33064325
[TBL] [Abstract][Full Text] [Related]
2. Survival in breast cancer patients with spine metastases: Prognostic assessment involving molecular markers.
Amelot A; Terrier LM; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Bonaccorsi R; Le Nail LR; Mathon B
Eur J Surg Oncol; 2020 Jun; 46(6):1021-1027. PubMed ID: 31899046
[TBL] [Abstract][Full Text] [Related]
3. Spine Metastasis in Elderly: Encouraging Results for Better Survival.
Beaufort Q; Terrier LM; Dubory A; Le Nail LR; Cook AR; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Mathon B; Amelot A
Spine (Phila Pa 1976); 2021 Jun; 46(11):751-759. PubMed ID: 33332789
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
5. Spinal metastases from thyroid cancer: Some prognostic factors.
Planty-Bonjour A; Dubory A; Terrier LM; Taïbi T; Cook AR; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Le Nail LR; Mathon B; Amelot A
Eur J Surg Oncol; 2022 Jan; 48(1):292-298. PubMed ID: 34503849
[TBL] [Abstract][Full Text] [Related]
6. Spinal metastases from lung cancer: Survival depends only on genotype, neurological and personal status, scarcely of surgical resection.
Amelot A; Terrier LM; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Bonaccorsi R; Le Nail LR; Mathon B
Surg Oncol; 2020 Sep; 34():51-56. PubMed ID: 32891353
[TBL] [Abstract][Full Text] [Related]
7. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
9. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
10. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
Pascale M; Azinwi CN; Marongiu B; Pesce G; Stoffel F; Roggero E
BMC Cancer; 2017 Sep; 17(1):651. PubMed ID: 28923109
[TBL] [Abstract][Full Text] [Related]
11. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy.
Taguchi S; Fukuhara H; Kakutani S; Takeshima Y; Miyazaki H; Suzuki M; Fujimura T; Nakagawa T; Igawa Y; Kume H; Homma Y
Asian Pac J Cancer Prev; 2014; 15(24):10729-33. PubMed ID: 25605166
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
15. Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).
Rasouli MA; Moradi G; Zareie B; Sofimajidpour H; Tozandehjani S; Zafari H; Gholami F; Shahsavari S; Hassani P; Mohammadian M
BMC Cancer; 2021 Dec; 21(1):1314. PubMed ID: 34876069
[TBL] [Abstract][Full Text] [Related]
16. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer.
Kim AH; Konety B; Chen Z; Schumacher F; Kutikov A; Smaldone M; Abouassaly R; Khanna A; Kim SP
Urology; 2018 Oct; 120():173-179. PubMed ID: 29990574
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):883-888. PubMed ID: 29976500
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
